Zai Lab finds latest target in Regeneron’s bispecific, paying up to $190M for Chinese rights Read more about Zai Lab finds latest target in Regeneron’s bispecific, paying up to $190M for Chinese rights
Zai Lab targets blood cancers in deal with Regeneron Read more about Zai Lab targets blood cancers in deal with Regeneron
Focusing on expanding our presence globally: Zai Lab chairman Read more about Focusing on expanding our presence globally: Zai Lab chairman
Zai Lab CEO discusses drug development, cancer drug Zejula's prospects Read more about Zai Lab CEO discusses drug development, cancer drug Zejula's prospects
Cancer therapy that fights brain tumours with electric fields brings hope to Hong Kong patients Read more about Cancer therapy that fights brain tumours with electric fields brings hope to Hong Kong patients
Zai study manuscript accepted by AAC on the antimicrobial activity of Omadacycline against isolates from China Read more about Zai study manuscript accepted by AAC on the antimicrobial activity of Omadacycline against isolates from China
Zai Lab added into the NASDAQ Biotechnology Index Read more about Zai Lab added into the NASDAQ Biotechnology Index